Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

BACKGROUND: While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy. To date, most biomarkers of response have been identified in the tumors thems...

Descripción completa

Detalles Bibliográficos
Autores principales: Subrahmanyam, Priyanka B., Dong, Zhiwan, Gusenleitner, Daniel, Giobbie-Hurder, Anita, Severgnini, Mariano, Zhou, Jun, Manos, Michael, Eastman, Lauren M., Maecker, Holden T., Hodi, F. Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840795/
https://www.ncbi.nlm.nih.gov/pubmed/29510697
http://dx.doi.org/10.1186/s40425-018-0328-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840795/
https://www.ncbi.nlm.nih.gov/pubmed/29510697
http://dx.doi.org/10.1186/s40425-018-0328-8

Ejemplares similares